FindTrial
Sign In

An Immuno-Dermatological disease registry in Indian Patients

An Immuno-Dermatological disease registry to understand the burden of Atopic dermatitis (AD), Alopecia areata (AA), and Vitiligo in Indian Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/07/055462
Enrollment
3000
Registered
2023-07-21
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L20- Atopic dermatitis

Interventions

None listed

Sponsors

Pfizer Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Be aged between 2 and 64 years old. 2. Clinical diagnosis of Vitiligo, AA or AD. 3. Evidence of a personally signed and dated informed consent/assent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion criteria

Exclusion criteria: Patients meeting any of the following criteria will not be included in the study: 1. Not willing to provide written informed consent. 2. Not willing for a follow-up visit.

Design outcomes

Primary

MeasureTime frame
to evaluate the epidemiological burden of mild, moderate and severe AD,vitiligo,and AA across enrolled dermatology centersTimepoint: followup visits take place at intervals at the investigators discretion.—

Secondary

MeasureTime frame
To elucidate the current diagnostic criteria and grading modalities for AD,vitiligo,and AA in India.Timepoint: followup visits take place at intervals at the investigators discretion.—

Countries

India

Contacts

Public ContactDr Charles Adhav

Inflammation & Immunology Medical Affairs, Pfizer India

Sonali.Karekar@pfizer.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026